Raymond James Financial Inc Cogent Biosciences, Inc. Transaction History
Raymond James Financial Inc
- $280 Billion
- Q2 2025
A detailed history of Raymond James Financial Inc transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 45 shares of COGT stock, worth $673. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45Holding current value
$673% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding COGT
# of Institutions
203Shares Held
117MCall Options Held
2.84MPut Options Held
828K-
Paradigm Biocapital Advisors LP New York, NY10.4MShares$155 Million3.47% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.49MShares$127 Million7.28% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$109 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$104 Million10.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.52MShares$97.6 Million0.0% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $984M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...